Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givosiran - Alnylam Pharmaceuticals

Drug Profile

Givosiran - Alnylam Pharmaceuticals

Alternative Names: ALN-AS1; GIVLAARI

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Amides; Amino sugars; Drug conjugates; Pyrrolidines; Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic-porphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatic-porphyria

Most Recent Events

  • 28 Nov 2023 Registered for Hepatic-porphyria (In adolescents, In adults) in Australia (SC)
  • 21 Jun 2023 Final efficacy and adverse event data from a phase I/II trial in Hepatic porphyria presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
  • 09 Mar 2023 Alnylam Pharmaceuticals entered in an agreement with Medison Pharma to commercialise Givosiran, in Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia, and Latvia and Israel
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top